SAN FRANCISCO, Feb. 23, 2017 /PRNewswire/ -- The inventor and developer of the original MEND protocol (metabolic
Since Dr. Bredesen's initial publication, he has made several new discoveries, including the recognition and naming of specific subtypes of Alzheimer's disease (published by Bredesen in 2015) and the recognition of specific toxic exposures contributing to Alzheimer's disease (published in 2015 and 2016). These discoveries and others led to the development of ReCODE™, the new version of The Bredesen Protocol™. "These latest discoveries greatly enhance our ability to determine the underlying causes of cognitive decline, thus improving our overall approach to reversing the decline, and strengthening the ability of our MPI Cognition Certified™ physicians to help their patients in need," said Bredesen.
The ReCODE™ version of The Bredesen Protocol™ will be the centerpiece of the upcoming Alzheimer's Reversal Immersion Program, the kickoff for an intensive one-year application of the improved protocol, which is limited to 100 qualifying pre-Alzheimer's, early stage, and mid-stage Alzheimer's participants, held in Indian Wells, California, on March 24 through 27, 2017.
Bredesen was the Founding President and CEO of the Buck Institute for Age Research in Novato, California, and Director of the Easton Center for Alzheimer's Research at UCLA.
800 450 [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/improved-reversals-of-cognitive-decline-in-alzheimers-disease-300412287.html
Subscribe to our Free Newsletters!
Hand hygiene is a simple and affordable technique to prevent infections.
Erythropoietin is a hormone secreted by kidneys in response to low oxygen levels in tissues ...
Local anesthesia is a type of anesthesia generally used to block pain sensation only in a specific ...View All